Paradigm Health is redefining the landscape of clinical research with its innovative, AI-powered platform designed to streamline the entire trial…
Read More
Terremoto Biosciences Secures $108 Million Series C to Advance Next-Generation AKT1 Inhibitors for Oncology and Rare Diseases
Terremoto Biosciences, a pioneering biotechnology company at the forefront of developing novel therapeutics targeting the PI3K/AKT pathway, announced today the…
Read More
Johnson & Johnson Forecasts Accelerated Growth in 2026 Driven by New Psoriasis Treatment, Icotyde, and Robust Pharma Portfolio
Johnson & Johnson (J&J) has reported a strong start to 2026, exceeding analyst expectations with robust first-quarter earnings and revising…
Read More
Amazon Web Services Launches AI Drug Discovery Platform to Accelerate Novel Therapy Development
Amazon Web Services (AWS) has unveiled a groundbreaking artificial intelligence (AI) application designed to significantly accelerate the design and testing…
Read More
US Food and Drug Administration Unveils Draft Guidance for Genome Editing Therapies, Prioritizing Safety Through Next-Generation Sequencing
The US Food and Drug Administration (FDA) has issued draft guidance aimed at enhancing the safety assessment of genome editing…
Read More
Novo Nordisk Forges Landmark AI Partnership with OpenAI to Revolutionize Drug Development Amidst Intensifying Competition
The pharmaceutical industry is witnessing an unprecedented surge in artificial intelligence (AI) adoption, with Novo Nordisk, a global leader in…
Read More
PHARMAP Congress 2026: Navigating the Future of Pharmaceuticals in Amsterdam
The pharmaceutical industry, a sector perpetually at the forefront of scientific innovation and facing a complex web of evolving challenges,…
Read More
EU Drug Exports Surge in 2025, Setting Record Trade Balance Amidst Geopolitical Tensions
New figures released by the European Union (EU) reveal a significant surge in the value of pharmaceutical trade across the…
Read More
Filspari Secures Landmark FDA Approval for Focal Segmental Glomerulosclerosis (FSGS) in Adults and Pediatric Patients Aged Eight and Above
Travere Therapeutics has achieved a significant milestone in the treatment of rare kidney diseases with the U.S. Food and Drug…
Read More
FDA Issues Complete Response Letter to Replimune’s RP1 for Advanced Melanoma
The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding Replimune Group’s Biologics License Application…
Read MoreYOU MAY HAVE MISSED
